Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9861622 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(11 months from now) | |
US8618135 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(11 months from now) | |
US9265758 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(11 months from now) | |
US9364470 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(11 months from now) | |
US10555938 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(11 months from now) | |
US9433617 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(11 months from now) | |
US10016404 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(11 months from now) | |
US7932268 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(3 years from now) |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regime...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9265812 | AMRYT | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
US8535695 | AMRYT | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
US9566246 | AMRYT | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
US8329198 | AMRYT | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
US11052126 | AMRYT | Method of treating diseases |
Feb, 2036
(11 years from now) | |
US10695397 | AMRYT | Method of treating diseases |
Feb, 2036
(11 years from now) | |
US10238709 | AMRYT | Method of treating diseases |
Feb, 2036
(11 years from now) | |
US11338011 | AMRYT | Method of treating diseases |
Feb, 2036
(11 years from now) | |
US11510963 | AMRYT | Method of treating diseases |
Feb, 2036
(11 years from now) | |
US11141457 | AMRYT | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Jun 26, 2023 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...
Dosage: CAPSULE, DELAYED RELEASE;ORAL